Brian Cheng
Stock Analyst at JP Morgan
(1.07)
# 3,550
Out of 4,732 analysts
57
Total ratings
34.78%
Success rate
-19.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.22 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $13.88 | +29.68% | 2 | Dec 16, 2024 | |
| BPMC Blueprint Medicines | Initiates: Overweight | $126 | $110.05 | +14.49% | 1 | Nov 14, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $19.24 | +45.53% | 4 | Nov 7, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $27 → $24 | $8.00 | +200.00% | 2 | Aug 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $61 → $55 | $9.50 | +478.95% | 3 | Aug 12, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $23.86 | +92.79% | 2 | Aug 8, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $39 → $33 | $3.33 | +890.99% | 2 | Jul 31, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $39 → $48 | $36.82 | +30.36% | 3 | Jul 25, 2024 | |
| MGX Metagenomi | Downgrades: Neutral | $16 → $6 | $2.61 | +129.89% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $9.99 | +140.24% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.11 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.62 | +708.28% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.82 | +339.56% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $12.39 | +85.63% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.15 | +34.53% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.49 | +2,739.76% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.83 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.91 | +560.50% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $4.67 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.96 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.24 | +1,512.90% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $16.79 | +406.25% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.45 | +181.88% | 1 | Aug 3, 2021 |
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.22
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $13.88
Upside: +29.68%
Blueprint Medicines
Nov 14, 2024
Initiates: Overweight
Price Target: $126
Current: $110.05
Upside: +14.49%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $19.24
Upside: +45.53%
iTeos Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $27 → $24
Current: $8.00
Upside: +200.00%
Intellia Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $61 → $55
Current: $9.50
Upside: +478.95%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $23.86
Upside: +92.79%
Kyverna Therapeutics
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $3.33
Upside: +890.99%
Protagonist Therapeutics
Jul 25, 2024
Maintains: Overweight
Price Target: $39 → $48
Current: $36.82
Upside: +30.36%
Metagenomi
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.61
Upside: +129.89%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $9.99
Upside: +140.24%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.11
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.62
Upside: +708.28%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.82
Upside: +339.56%
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $12.39
Upside: +85.63%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.15
Upside: +34.53%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.49
Upside: +2,739.76%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.83
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.91
Upside: +560.50%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $4.67
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.96
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $1.24
Upside: +1,512.90%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $16.79
Upside: +406.25%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.45
Upside: +181.88%